Add BrightSurf on Google Email

Emory Health Sciences


Safety data favor norepinephrine over dopamine for shock

An editorial in NEJM suggests that norepinephrine is a safer option than dopamine for stabilizing blood pressure in shock patients, citing a European clinical trial. The study found no overall difference in death rates between the two treatments, but higher mortality rates in patients with cardiogenic shock treated with dopamine.

SourceEmory Health Sciences·JournalNew England Journal of Medicine·DateMar 3, 2010

Cells can read damaged DNA without missing a beat

Researchers found that cells' DNA-reading machinery can bypass certain types of damaged DNA, leading to mutagenesis and potential antibiotic resistance in bacteria. This discovery has important implications for understanding how bacteria develop resistance to antibiotics.

SourceEmory Health Sciences·JournalProceedings of the National Academy of Sciences·DateFeb 9, 2010

Ancient remains put teeth into Barker hypothesis

The study found that tooth enamel defects in ancient humans were associated with shortened lifespans, suggesting a link between early life stress and adult diseases. The research supports the Barker hypothesis, which proposes that many adult diseases originate during fetal development and early childhood.

SourceEmory Health Sciences·JournalEvolutionary Anthropology Issues News and Reviews·DateFeb 4, 2010

Brain scientists extend map of fear memory formation

Researchers have extended the fear map to include the prelimbic cortex, revealing its importance in emotional regulation. The study found that mice lacking a critical growth factor in the prelimbic cortex struggle to remember to fear electric shocks, suggesting a potential link to anxiety disorders.

SourceEmory Health Sciences·JournalProceedings of the National Academy of Sciences·DateJan 27, 2010

New class of brain-protecting drugs emerging

Researchers at Emory University School of Medicine have identified a novel compound, 7,8-dihydroxyflavone, that mimics the brain's growth factor and protects against neurological disease damage. The flavonoid compound shows potential as a new class of brain-protecting drugs with low chronic toxicity.

SourceEmory Health Sciences·JournalProceedings of the National Academy of Sciences·DateJan 25, 2010